Bakhu Holdings Corp (OTCMKTS:BKUH) Stock In Focus: Company Appoints Two Independent Directors

Bakhu Holdings Corp (OTCMKTS:BKUH) on August 17, 2022, the addition of two independent members to the Board of Directors, Moshe Morgenstern, 44, and Tom Vaknin, 33.

Trading Data

On Wednesday, BKUH stock ended flat at $1.20 with more than 400 shares, compared to its average volume of 116 shares. The stock moved within a range of $1.2000 – 1.2000 after opening trade at $1.20.

Bakhu Holdings Appoints Two Independent Directors to Its Board

The company has exclusive North American rights for growing select cannabinoids in proprietary bioreactors. This is done with consistent qualitative as well as quantitative attributes. The management views it as a significant discount on traditional cultivation and manufacturing processes.

President and CEO Evripides Drakos said that the company is pleased on showing the outside perspective of two significant international businessmen. Drakos expects them to exploit rights for sublicensing a patented cell replacement process.

The firm accepted the resignations of Juan Carlos Garcia La Suerna Garcia and Sagi Rozen as members of the Board. While Rozen will continue the relationship with the company through the position of Senior Board Advisor, Garcia will take on the role of Chief Financial Officer

Co-Founder and Co-CEO of Pay.com, the US amongst other regions, Vaknin’s firm is an EU-regulated payment institution. He was also the Co-Founder and Chief Technical Officer of Engage.com, Tel Aviv from August 2018 to November 2020. He is a Bachelor of Arts in MIS Management Information Systems from The College for Academic Studies, Tel Aviv.

Morgenstern has close to two decades of experience in global business development and management in insurance and finance. He was awarded the Best Chief Information Officer in 2020 at Israel’s Conference of Information Technology.

Key Quote

“We are pleased to add the outside perspective of two prominent international businessmen to the insight of our current officers and directors to exploit our rights to sublicense a patented cell replacement process,” President and CEO Evripides Drakos said in making the announcement.